2.05
price up icon0.99%   0.02
after-market After Hours: 2.05
loading
Vistagen Therapeutics Inc stock is traded at $2.05, with a volume of 117.08K. It is up +0.99% in the last 24 hours and down -14.94% over the past month. Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$2.03
Open:
$2.04
24h Volume:
117.08K
Relative Volume:
0.86
Market Cap:
$68.98M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-1.5272
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
-0.49%
1M Performance:
-14.94%
6M Performance:
-21.15%
1Y Performance:
-36.92%
1-Day Range:
Value
$1.99
$2.07
1-Week Range:
Value
$1.94
$2.2199
52-Week Range:
Value
$1.90
$4.21

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
Name
Vistagen Therapeutics Inc
Name
Phone
650-577-3600
Name
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
Employee
48
Name
Twitter
@vistagen
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
VTGN's Discussions on Twitter

Compare VTGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VTGN
Vistagen Therapeutics Inc
2.05 68.98M 875.70K -39.57M -33.65M -1.3423
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-07-23 Upgrade Jefferies Hold → Buy
Aug-07-23 Upgrade Maxim Group Hold → Buy
Jul-22-22 Downgrade Jefferies Buy → Hold
Jul-22-22 Downgrade Robert W. Baird Outperform → Neutral
Jul-22-22 Downgrade William Blair Outperform → Mkt Perform
May-20-21 Initiated Robert W. Baird Outperform
Feb-18-21 Initiated Jefferies Buy
Jan-04-21 Upgrade William Blair Mkt Perform → Outperform
Jun-27-18 Initiated Maxim Group Buy
Feb-08-18 Reiterated Chardan Capital Markets Buy
Mar-28-17 Initiated Maxim Group Buy
View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

pulisher
Jun 18, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise

Jun 17, 2025
pulisher
Jun 17, 2025

Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics Inc Reports Q1 Revenue of $0.49M, Surpassi - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen (VTGN) Reports Decrease in FY25 Revenue, Advances Key Medical Programs | VTGN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics, Inc. SEC 10-K Report - TradingView

Jun 17, 2025
pulisher
Jun 16, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For - GuruFocus

Jun 16, 2025
pulisher
Jun 14, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Holdings Increased by Millennium Management LLC - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Vistagen Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView

Jun 13, 2025
pulisher
Jun 12, 2025

Vistagen Earnings Preview: Late-Stage Neuroscience Biotech to Unveil FY2025 Performance - Stock Titan

Jun 12, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Has $405,000 Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Acquires New Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Earnings Preview: What to Expect from $VTGN Amid Shifting Investor Sentiment | VTGN Stock - paginasiete.bo

Jun 07, 2025
pulisher
Jun 07, 2025

VISTAGEN THERAPEUTICS Earnings Preview: Recent $VTGN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Jun 07, 2025
pulisher
Jun 07, 2025

Vistagen Therapeutics (VTGN) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

Jun 07, 2025
pulisher
Jun 05, 2025

VistaGen at Jefferies: Expanding Horizons in Social Anxiety Treatment By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 04, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN St - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - MarketScreener

Jun 02, 2025
pulisher
Jun 02, 2025

Major Social Anxiety Treatment Breakthrough: Phase 3 Trial Results Coming Q4 2025What to Expect - Stock Titan

Jun 02, 2025
pulisher
May 31, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat

May 31, 2025
pulisher
May 28, 2025

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise

May 28, 2025
pulisher
May 28, 2025

Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 23, 2025

Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference - BioSpace

May 23, 2025
pulisher
May 19, 2025

Ellis Martin Report: Vistagen Therapeutics Inc. (NASDAQ:VTGN) CEO Shawn SinghA Revolutionary Fast Acting Nasal Spray Targeting Social Anxiety Disorder - ABN Newswire

May 19, 2025
pulisher
May 12, 2025

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq

May 12, 2025
pulisher
May 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat

May 11, 2025
pulisher
May 08, 2025

254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat

May 08, 2025
pulisher
May 06, 2025

Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

May 06, 2025
pulisher
May 05, 2025

Form 8-KCurrent report - ADVFN

May 05, 2025
pulisher
May 04, 2025

Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

May 04, 2025
pulisher
Apr 29, 2025

JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Apr 29, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 24, 2025

JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Apr 24, 2025
pulisher
Apr 17, 2025

Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan

Apr 17, 2025
pulisher
Apr 17, 2025

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace

Apr 17, 2025
pulisher
Apr 08, 2025

Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World

Apr 08, 2025

Vistagen Therapeutics Inc Stock (VTGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Cap:     |  Volume (24h):